Phase 1 Thyroid Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to give written consent themselves, or have a guardian who can do so on their behalf
• People who are over 18 years of age
• People who have been diagnosed with a side effect from immunotherapy treatment that is clinically suspected to be caused by a specific part of the immune system (called IL-17) (confirm with trial site)
• People who are currently being treated with, or are planned to be treated with, steroid medications to manage their immunotherapy side effects
• People who have a confirmed diagnosis of an advanced or metastatic solid organ cancer (meaning cancer that has spread and is not being treated with the goal of a cure) that is being treated with immunotherapy
• People who have tested negative for tuberculosis within 30 days before starting the trial — this can be shown by either a skin test (PPD) with a negative result, or a negative blood test (QuantiFERON)
• People who had a positive skin test (PPD) but have a history of BCG vaccination may still be eligible if their QuantiFERON blood test is negative
• People who had a positive skin test or an unclear or positive QuantiFERON result may still be eligible if all of the following apply: they have no tuberculosis symptoms (such as fever, shortness of breath, cough, or night sweats); they have a documented history of completing a full course of tuberculosis preventive treatment; they have not been known to be exposed to active tuberculosis since completing that treatment; and a chest X-ray taken within 3 months before the first dose shows no signs of active tuberculosis

Who may not be able to join:

• People whose kidneys are not filtering blood well enough (estimated creatinine clearance below 40 mg/min) (confirm with trial site)
• People who are experiencing active thoughts of suicide or severe depression at the time of joining, or who score above 20 on a standard depression questionnaire (PHQ-9)
• People who have a history of previous suicide attempts
• People who score between 5 and 20 on the PHQ-9 depression questionnaire and do not have an established mental health provider who can confirm their depression is stable
• People who have had a problem with drug or alcohol misuse within the past 6 months
• People who, in the investigator's opinion, need additional immune-suppressing treatments beyond steroids and the study drug
• People who have a known allergy or medical reason they cannot take the study drug (brodalumab) or steroids
• People who have previously been treated with brodalumab
• People who are pregnant, breastfeeding, or are not willing or able to use highly effective contraception during treatment and for at least 4 weeks after the last dose of the study drug — this applies to people who were assigned female at birth, unless they have had a surgical procedure that prevents pregnancy or have been confirmed to be at least 2 years past menopause (confirmed by a hormone blood test)
• People who are planning to become pregnant while in the study or within 4 weeks of the last dose of the study drug
• People who currently have a serious infection that requires intravenous (IV) antibiotic or antiviral treatment
• People with evidence of active hepatitis B, hepatitis C, or active tuberculosis
• People who have a history of latent (inactive) tuberculosis that was never treated or was not fully treated according to standard medical care
• People who have a history of Crohn's disease, or who currently have it
• People who have had a heart attack, unstable chest pain (angina), or stroke within the 12 months before starting the study drug
• People who have any other medical condition or abnormal heart test result that, in the investigator's opinion, could make participation harmful
• People who have any medical condition or treatment that, in the investigator's opinion, could interfere with the study or make results unreliable
• People with serious heart disease, including advanced heart failure
• People with significantly elevated liver enzyme levels (AST or ALT) on at least two separate tests (confirm with trial site for specific thresholds)
• People with elevated bilirubin levels at or above a certain level (confirm with trial site)
• People with low blood cell counts unrelated to their immunotherapy side effects — including low white blood cells, low neutrophils, low platelets, or low haemoglobin (confirm with trial site for specific thresholds)
• People who are planning to continue or start cancer treatment aimed at a cure at the time of joining the trial
• People who are currently participating in another treatment clinical trial or who have received an investigational drug within 4 weeks before the screening visit
• People with a previously diagnosed autoimmune disease, or who have taken immune-suppressing medications in a timeframe that could make it difficult to interpret the study drug's effects (confirm with trial site)
• People who are planning to use, or have used within 28 days before starting the trial, immune-suppressing medications other than steroids (such as infliximab, vedolizumab, or tocilizumab)
• People who have received a live-virus vaccine within 4 weeks before the first dose of the study drug

Important: Always verify eligibility with the trial site directly before applying.